BackDicerna Pharmaceuticals Overview

Dicerna Pharmaceuticals Other Current Assets

Dicerna Pharmaceuticals's other current assets is $17M.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$17.27M
46.87% YoYΔ $5.51M vs prior year quarter

Peer average / median

Loading

Dicerna Pharmaceuticals Other Current Assets History

Loading

Dicerna Pharmaceuticals vs. peers: Other Current Assets Comparison

Loading

Dicerna Pharmaceuticals Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Dicerna Pharmaceuticals (DRNA) FAQ

Dicerna Pharmaceuticals (DRNA) currently reports a other current assets of $17M as of September 2021. That compares with $12M in the prior-year period — up 46.9% year over year. Use the charts on this page to explore Dicerna Pharmaceuticals's other current assets history and peer comparisons.

Dicerna Pharmaceuticals's other current assets increased from $12M to $17M — a 46.9% year-over-year increase (period ending September 2021). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Dicerna Pharmaceuticals reported $17M in other current assets as of September 2021. That compares with $12M in the prior-year period — up 46.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current assets of $17M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Dicerna Pharmaceuticals, and consider following DRNA for alerts when major investors trade the stock.

Dicerna Pharmaceuticals is classified in the Healthcare sector. On other current assets, it currently shows $17M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DRNA with unrelated industries.